Soluble inflammatory markers as predictors of hepatocellular damage and therapeutic response in chronic hepatitis C

Brazilian Journal of Infectious Diseases

Volumn 13, Issue 5, 2009, Pages 375-382

  Moura, Alexandre Sampaio ^a   Carmo, Ricardo Andrade ^b   Teixeira, Antonio Lucio ^a   Rocha, Manoel Otávio da Costa ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b Belo Horizonte City Health Department   (Brazil)

Author keywords

Chemokines; Hepatitis C; Interferon alpha; Liver fibrosis; Tumor necrosis factor receptor

Indexed keywords

ALPHA INTERFERON; CHEMOKINE; CXCL9 CHEMOKINE; CYTOKINE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; RANTES; RIBAVIRIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; BIOLOGICAL MARKER; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2;

ARTICLE; DISEASE COURSE; HEPATITIS C; HUMAN; IMMUNE RESPONSE; INFLAMMATION; LIVER CANCER; LIVER CELL DAMAGE; LIVER CIRRHOSIS; LIVER HISTOLOGY; PREDICTION; TH1 CELL; TREATMENT RESPONSE; BLOOD; IMMUNOLOGY; PATHOLOGY; REVIEW;

BIOLOGICAL MARKERS; CHEMOKINES; DISEASE PROGRESSION; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; TH1 CELLS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77953712527     PISSN: 14138670     EISSN: None     Source Type: Journal    
DOI: 10.1590/S1413-86702009000500013     Document Type: Article

References (126)

1. Shepard C.W., Finelli L., Alter M.J. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005; 5: 558-67.
2. Perz J.F., Armstrong G.L., Farrington L.A., et al. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 2006; 45: 529-38.
3. Poynard T., Bedossa P., Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997; 349: 825-32.
4. Poynard T., Ratziu V., Charlotte F., et al. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C. J Hepatol 2001; 34: 730-9.
5. Benhamou Y., Bochet M., Di Martino V., et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology 1999; 30: 1054-8.
6. Benvegnu L., Fattovich G., Noventa F., et al. Concurrent hepatitis B and C virus infection and risk of hepatocellular carcinoma in cirrhosis. A prospective study. Cancer 1994; 74: 2442-8.
7. Leandro G., Mangia A., Hui J., et al. Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. Gastroenterology 2006; 130: 1636-42.
8. Hui J.M., Sud A., Farrell G.C., et al. Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression. Gastroenterology 2003; 125: 1695-704.
9. Shaheen A.A., Wan A.F., Myers R.P. FibroTest and FibroScan for the prediction of hepatitis C-related fibrosis: a systematic review of diagnostic test accuracy. Am J Gastroenterol 2007; 102: 2589-600.
10. Wai C.T., Greenson J.K., Fontana R.J., et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003; 38: 518-26.
11. Poynard T., McHutchison J., Manns M., et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002; 122: 1303-13.
12. Fried M.W., Shiffman M.L., Reddy K.R., et al. Peginterferon alfa- 2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-982.
13. Manns M.P., McHutchison J.G., Gordon S.C., et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-965.
14. Lee S.S., Heathcote E.J., Reddy K.R., et al. Prognostic factors and early predictability of sustained viral response with peginterferon alfa-2a (40KD). J Hepatol 2002; 37: 500-506.
15. Mihm U., Herrmann E., Sarrazin C, Zeuzem S. Review article: predicting response in hepatitis C virus therapy. Aliment Pharmacol Ther 2006; 23: 1043-1054.
16. Napoli J., Bishop G.A., McGuinness P.H., et al. Progressive liver injury in chronic hepatitis C infection correlates with increased intrahepatic expression of Th1-associated cytokines. Hepatology 1996; 24: 759-765.
17. Sobue S., Nomura T., Ishikawa T., et al. Th1/Th2 cytokine profiles and their relationship to clinical features in patients with chronic hepatitis C virus infection. J Gastroenterol 2001; 36: 544-551.
18. Ghany M.G., Kleiner D.E., Alter H., et al. Progression of fibrosis in chronic hepatitis C. Gastroenterology 2003; 124: 97-104.
19. Chang K.M., Rehermann B., Chisari F.V. Immunopathology of hepatitis C. Springer Semin Immunopathol 1997; 19: 57-68.
20. Wejstal R. Immune-mediated liver damage in chronic hepatitis C. Scand J Gastroenterol 1995; 30: 609-13.
21. Luster A.D. Chemokines-chemotactic cytokines that mediate inflammation. N Engl J Med 1998; 338: 436-445.
22. Baggiolini M., Dewald B., Moser B. Human chemokines: an update. Annu Rev Immunol 1997; 15: 675-705.
23. Mackay C.R. Chemokines: what chemokine is that? Curr Biol 1997; 7: R384-6.
24. Gerard C., Rollins B.J. Chemokines and disease. Nat Immunol 2001; 2: 108-115.
25. Kunkel S.L. Through the looking glass: the diverse in vivo activities of chemokines. J Clin Invest 1999; 104: 1333-4334.
26. Charo I.F., Ransohoff R.M. The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med 2006; 354: 610-621.
27. Ono S.J., Nakamura T., Miyazaki D., et al. Chemokines: roles in leukocyte development, trafficking, and effector function. J Allergy Clin Immunol 2003; 111: 1185-99.
28. Rot A., von Andrian U.H. Chemokines in innate and adaptive host defense: basic chemokinese grammar for immune cells. Annu Rev Immunol 2004; 22: 891-928.
29. Zlotnik A. Yoshie O. Chemokines: a new classification system and their role in immunity. Immunity 2000; 12: 121-7.
30. Rollins B.J. Chemokines. Blood 1997; 90: 909-28.
31. Bonecchi R., Bianchi G., Bordignon P.P., et al. Differential expression of chemokine receptors and chemotactic responsiveness of type 1 T helper cells (Th1s) and Th2s. J Exp Med 1998; 187: 129-34.
32. Koziel M.J. Cytokines in viral hepatitis. Seminars in liver disease 1999; 19: 157-69.
33. Apolinario A., Garcia Monzon C. Role of chemokines in the pathogenesis of liver diseases. Rev Esp Enferm Dig 2003; 95: 614-620, 07-13.
34. Shields P.L., Morland C.M., Salmon M., et al. Chemokine and chemokine receptor interactions provide a mechanism for selective T cell recruitment to specific liver compartments within hepatitis C-infected liver. J Immunol 1999; 163: 6236-43.
35. Larrubia J.R., Calvino M., Benito S., et al. The role of CCR5/ CXCR3 expressing CD8+ cells in liver damage and viral control during persistent hepatitis C virus infection. J Hepatol 2007; 47: 632-41.
36. Goulding C., McManus R., Murphy A., et al. The CCR5-delta32 mutation: impact on disease outcome in individuals with hepatitis C infection from a single source. Gut 2005; 54: 1157-61.
37. Hellier S., Frodsham A.J., Hennig B.J., et al. Association of genetic variants of the chemokine receptor CCR5 and its ligands, RANTES and MCP-2, with outcome of HCV infection. Hepatology 2003; 38: 1468-76.
38. Butera D., Marukian S., Iwamaye A.E., et al. Plasma chemokine levels correlate with the outcome of antiviral therapy in patients with hepatitis C. Blood 2005; 106: 1175-82.
39. Hechtman D.H., Cybulsky M.I., Fuchs H.J., et al. Intravascular IL-8. Inhibitor of polymorphonuclear leukocyte accumulation at sites of acute inflammation. J Immunol 1991; 147: 883-92.
40. Clark-Lewis I., Mattioli I., Gong J.H., Loetscher P. Structure- function relationship between the human chemokine receptor CXCR3 and its ligands. J Biol Chem 2003; 278: 289-95.
41. Narumi S., Yoneyama H., Inadera H., et al. TNF-alpha is a potent inducer for IFN-inducible protein-10 in hepatocytes and unaffected by GM-CSF in vivo, in contrast to IL-1beta and IFN-gamma. Cytokine 2000; 12: 1007-16.
42. Narumi S., Tominaga Y., Tamaru M., et al. Expression of IFN- inducible protein-10 in chronic hepatitis. J Immunol 1997; 158: 5536-44.
43. Apolinario A., Majano P.L., Lorente R., et al. Gene expression profile of T-cell-specific chemokines in human hepatocyte-derived cells: evidence for a synergistic inducer effect of cytokines and hepatitis C virus proteins. J Viral Hepat 2005; 12: 27-37.
44. Iredale J.P. Cirrhosis: new research provides a basis for rational and targeted treatments. BMJ 2003; 327: 143-7.
45. Bonacchi A., Romagnani P., Romanelli R.G., et al. Signal transduction by the chemokine receptor CXCR3: activation of Ras/ERK, Src, and phosphatidylinositol 3-kinase/Akt controls cell migration and proliferation in human vascular pericytes. J Biol Chem 2001; 276: 9945-54.
46. Apolinario A., Diago M., Lo Iacono O., et al. Increased circulating and intrahepatic T-cell-specific chemokines in chronic hepatitis C: relationship with the type of virological response to peginterferon plus ribavirin combination therapy. Aliment Pharmacol Ther 2004; 19: 551-62.
47. Harvey C.E., Post J.J., Palladinetti P., et al. Expression of the chemokine IP-10 (CXCL10) by hepatocytes in chronic hepatitis C virus infection correlates with histological severity and lobular inflammation. J Leukoc Biol 2003; 74: 360-9.
48. Apolinario A., Majano P.L., Alvarez-Perez E., et al. Increased expression of T cell chemokines and their receptors in chronic hepatitis C: relationship with the histological activity of liver disease. Am J Gastroenterol 2002; 97: 2861-70.
49. Wertheimer A.M., Polyak S.J., Leistikow R, Rosen H.R. Engulfment of apoptotic cells expressing HCV proteins leads to differential chemokine expression and STAT signaling in human dendritic cells. Hepatology 2007; 45: 1422-32.
50. Khabar K.S., Al-Zoghaibi F., Al-Ahdal M.N., et al. The alpha chemokine, interleukin 8, inhibits the antiviral action of interferon alpha. J Exp Med 1997; 186: 1077-85.
51. Polyak S.J., Khabar K.S., Paschal D.M., et al. Hepatitis C virus nonstructural 5A protein induces interleukin-8, leading to partial inhibition of the interferon-induced antiviral response. J Virol 2001; 75: 6095-106.
52. Polyak S.J., Khabar K.S., Rezeiq M.Gretch D.R. Elevated levels of interleukin-8 in serum are associated with hepatitis C virus infection and resistance to interferon therapy. J Virol 2001; 75: 6209-11.
53. Neuman M.G., Benhamou J.P., Marcellin P., et al. Cytokine- chemokine and apoptotic signatures in patients with hepatitis C. Transl Res 2007; 149: 126-36.
54. Kaplanski G., Farnarier C., Payan M.J., et al. Increased levels of soluble adhesion molecules in the serum of patients with hepatitis C. Correlation with cytokine concentrations and liver inflammation and fibrosis. Dig Dis Sci 1997; 42: 2277-84.
55. Tachibana Y., Nakamoto Y., Mukaida N.Kaneko S. Intrahepatic interleukin-8 production during disease progression of chronic hepatitis C. Cancer Lett 2007; 251: 36-42.
56. Kusano F., Tanaka Y., Marumo F.Sato C. Expression of C-C chemokines is associated with portal and periportal inflammation in the liver of patients with chronic hepatitis C. Lab Invest 2000; 80: 415-22.
57. Nischalke H.D., Nattermann J., Fischer H.P., et al. Semiquantitative analysis of intrahepatic CC-chemokine mRNas in chronic hepatitis C. Mediators Inflamm 2004; 13: 357-9.
58. Bonacchi A., Petrai I., Defranco R.M., et al. The chemokine CCL21 modulates lymphocyte recruitment and fibrosis in chronic hepatitis C. Gastroenterology 2003; 125: 1060-76.
59. Yamauchi K., Akbar S.M., Horiike N., et al. Increased serum levels of macrophage inflammatory protein-3alpha in chronic viral hepatitis: prognostic importance of macrophage inflammatory protein-3alpha during interferon therapy in chronic hepatitis C. J Viral Hepat 2002; 9: 213-20.
60. Bradley J.R. TNF-mediated inflammatory disease. J Pathol 2008; 214: 149-60.
61. Radkowski M., Bednarska A., Horban A., et al. Infection of primary human macrophages with hepatitis C virus in vitro: induction of tumour necrosis factor-alpha and interleukin 8. J Gen Virol 2004; 85: 47-59.
62. Gehr G., Gentz R., Brockhaus M., et al. Both tumor necrosis factor receptor types mediate proliferative signals in human mononuclear cell activation. J Immunol 1992; 149: 911-7.
63. Ware C.F., Crowe P.D., Vanarsdale T.L., et al. Tumor necrosis factor (TNF) receptor expression in T lymphocytes. Differential regulation of the type I TNF receptor during activation of resting and effector T cells. J Immunol 1991; 147: 4229-38.
64. Liu Z.G., Han J. Cellular responses to tumor necrosis factor. Curr Issues Mol Biol 2001; 3: 79-90.
65. Kallinowski B., Haseroth K., Marinos G., et al. Induction of tumour necrosis factor (TNF) receptor type p55 and p75 in patients with chronic hepatitis C virus (HCV) infection. Clin Exp Immunol 1998; 111: 269-77.
66. Nophar Y., Kemper O., Brakebusch C., et al. Soluble forms of tumor necrosis factor receptors (TNF-Rs). The cDNA for the type I TNF-R, cloned using amino acid sequence data of its soluble form, encodes both the cell surface and a soluble form of the receptor. EMBO J 1990; 9: 3269-78.
67. Engelmann H., Novick D.Wallach D. Two tumor necrosis factor- binding proteins purified from human urine. Evidence for immunological cross-reactivity with cell surface tumor necrosis factor receptors. J Biol Chem 1990; 265: 1531-6.
68. Olsson I., Lantz M., Nilsson E., et al. Isolation and characterization of a tumor necrosis factor binding protein from urine. Eur J Haematol 1989; 42: 270-5.
69. Seckinger P., Isaaz S.Dayer J.M. Purification and biologic characterization of a specific tumor necrosis factor alpha inhibitor. J Biol Chem 1989; 264: 11966-73.
70. Wang J., Al-Lamki R.S., Zhang H., et al. Histamine antagonizes tumor necrosis factor (TNF) signaling by stimulating TNF receptor shedding from the cell surface and Golgi storage pool. J Biol Chem 2003; 278: 21751-60.
71. Aderka D. The potential biological and clinical significance of the soluble tumor necrosis factor receptors. Cytokine Growth Factor Rev 1996; 7: 231-40.
72. Porteu F., Nathan C. Shedding of tumor necrosis factor receptors by activated human neutrophils. J Exp Med 1990; 172: 599-607.
73. Porteu F., Brockhaus M., Wallach D., et al. Human neutrophil elastase releases a ligand-binding fragment from the 75-kDa tumor necrosis factor (TNF) receptor. Comparison with the proteolytic activity responsible for shedding of TNF receptors from stimulated neutrophils. J Biol Chem 1991; 266: 18846-53.
74. Porteu F. Hieblot C. Tumor necrosis factor induces a selective shedding of its p75 receptor from human neutrophils. J Biol Chem 1994; 269: 2834-40.
75. Lien E., Liabakk N.B., Johnsen A.C., et al. Polymorphonuclear granulocytes enhance lipopolysaccharide-induced soluble p75 tumor necrosis factor receptor release from mononuclear cells. Eur J Immunol 1995; 25: 2714-7.
76. Joyce D.A., Gibbons D.P., Green P., et al. Two inhibitors of pro- inflammatory cytokine release, interleukin-10 and interleukin-4, have contrasting effects on release of soluble p75 tumor necrosis factor receptor by cultured monocytes. Eur J Immunol 1994; 24: 2699-705.
77. Lantz M., Malik S., Slevin M.L.Olsson I. Infusion of tumor necrosis factor (TNF) causes an increase in circulating TNF-binding protein in humans. Cytokine 1990; 2: 402-6.
78. Yoshioka K., Kakumu S., Arao M., et al. Tumor necrosis factor alpha production by peripheral blood mononuclear cells of patients with chronic liver disease. Hepatology 1989; 10: 769-73.
79. Kountouras J., Zavos C.Chatzopoulos D. Apoptosis in hepatitis C. J Viral Hepat 2003; 10: 335-42.
80. Neuman M.G., Benhamou J.P., Malkiewicz I.M., et al. Cytokines as predictors for sustained response and as markers for immunomodulation in patients with chronic hepatitis C. Clin Biochem 2001; 34: 173-82.
81. Hassan M.I., Kassim S.K., Ahmad M.I.Fawzy S. Antiproliferative effect of hepatitis C virus on mitogen-stimulated peripheral blood mononuclear cells: potential role in viral persistence in Egyptian patients. Clin Biochem 2007; 40: 1173-9.
82. Tilg H., Vogel W.Dinarello C.A. Interferon-alpha induces circulating tumor necrosis factor receptor p55 in humans. Blood 1995; 85: 433-5.
83. Neuman M.G., Benhamou J.P., Malkiewicz I.M., et al. Kinetics of serum cytokines reflect changes in the severity of chronic hepatitis C presenting minimal fibrosis. J Viral Hepat 2002; 9: 134-40.
84. Durante-Mangoni E., Zampino R., Marrone A., et al. Hepatic steatosis and insulin resistance are associated with serum imbalance of adiponectin/tumour necrosis factor-alpha in chronic hepatitis C patients. Aliment Pharmacol Ther 2006; 24: 1349-57.
85. Adinolfi L.E., Gambardella M., Andreana A., et al. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 2001; 33: 1358-64.
86. Hourigan L.F., Macdonald G.A., Purdie D., et al. Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis. Hepatology 1999; 29: 1215-9.
87. Diez-Ruiz A., Tilz G.P., Zangerle R., et al. Soluble receptors for tumour necrosis factor in clinical laboratory diagnosis. Eur J Haematol 1995; 54: 1-8.
88. Van Zee K.J., Kohno T., Fischer E., et al. Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor alpha in vitro and in vivo. Proc Natl Acad Sci U S A 1992; 89: 4845-9.
89. Zylberberg H., Rimaniol A.C., Pol S., et al. Soluble tumor necrosis factor receptors in chronic hepatitis C: a correlation with histological fibrosis and activity. J Hepatol 1999; 30: 185-91.
90. Kakumu S., Okumura A., Ishikawa T., et al. Serum levels of IL-10, IL-15 and soluble tumour necrosis factor-alpha (TNF-alpha) receptors in type C chronic liver disease. Clin Exp Immunol 1997; 109: 458-63.
91. Itoh Y., Okanoue T., Ohnishi N., et al. Serum levels of soluble tumor necrosis factor receptors and effects of interferon therapy in patients with chronic hepatitis C virus infection. American J Gastroenterol 1999; 94: 1332-40.
92. Strader D.B., Wright T., Thomas D.L.Seeff L.B. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004; 39: 1147-71.
93. de Araujo E.S., Mendonca J.S., Barone A.A., et al. Consensus of the Brazilian Society of Infectious Diseases on the management and treatment of hepatitis C. Braz J Infect Dis 2007; 11: 446-50.
94. Feld J.J., Hoofnagle J.H. Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature 2005; 436: 967-72.
95. Tilg H. New insights into the mechanisms of interferon alfa: an immunoregulatory and anti-inflammatory cytokine. Gastroenterology 1997; 112: 1017-21.
96. Tam R.C., Pai B., Bard J., et al. Ribavirin polarizes human T cell responses towards a Type 1 cytokine profile. J Hepatol 1999; 30: 376-82.
97. Guidotti L.G., Chisari F.V. Noncytolytic control of viral infections by the innate and adaptive immune response. Ann Rev Immunol 2001; 19: 65-91.
98. Rehermann B., Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol 2005; 5: 215-29.
99. Kamal S.M., Ismail A., Graham C.S., et al. Pegylated interferon alpha therapy in acute hepatitis C: relation to hepatitis C virus-specific T cell response kinetics. Hepatology 2004; 39: 1721-31.
100. Kamal S.M., Fehr J., Roesler B., et al. Peginterferon alone or with ribavirin enhances HCV-specific CD4 T-helper 1 responses in patients with chronic hepatitis C. Gastroenterology 2002; 123: 1070-83.
101. Cramp M.E., Rossol S., Chokshi S., et al. Hepatitis C virus-specific T-cell reactivity during interferon and ribavirin treatment in chronic hepatitis C. Gastroenterology 2000; 118: 346-55.
102. Nelson D.R., Marousis C.G., Ohno T., et al. Intrahepatic hepatitis C virus-specific cytotoxic T lymphocyte activity and response to interferon alfa therapy in chronic hepatitis C. Hepatology 1998; 28: 225-30.
103. Lechner F., Gruener N.H., Urbani S., et al. CD8+ T lymphocyte responses are induced during acute hepatitis C virus infection but are not sustained. Eur J Immunol 2000; 30: 2479-87.
104. Woitas R.P., Lechmann M., Jung G., et al. CD30 induction and cytokine profiles in hepatitis C virus core-specific peripheral blood T lymphocytes. J Immunol 1997; 159: 1012-8.
105. Yang Y.F., Tomura M., Iwasaki M., et al. IFN-alpha acts on T-cell receptor-triggered human peripheral leukocytes to up-regulate CCR5 expression on CD4+ and CD8+ T cells. J Clin Immunol 2001; 21: 402-9.
106. Nattermann J., Nischalke H.D., Feldmann G., et al. Binding of HCV E2 to CD81 induces RANTES secretion and internalization of CC chemokine receptor 5. J Viral Hepat 2004; 11: 519-26.
107. Ahlenstiel G., Berg T., Woitas R.P., et al. Effects of the CCR5-Delta32 mutation on antiviral treatment in chronic hepatitis C. J Hepatol 2003; 39: 245-52.
108. Glas J., Torok H.P., Simperl C., et al. The Delta 32 mutation of the chemokine-receptor 5 gene neither is correlated with chronic hepatitis C nor does it predict response to therapy with interferon-alpha and ribavirin. Clin Immunol 2003; 108: 46-50.
109. von-Andrian U.H. Mackay C.R. T-cell function and migration. Two sides of the same coin. N Engl J Med 2000; 343: 1020-34.
110. Diago M., Castellano G., Garcia-Samaniego J., et al. Association of pretreatment serum interferon gamma inducible protein 10 levels with sustained virological response to peginterferon plus ribavirin therapy in genotype 1 infected patients with chronic hepatitis C. Gut 2006; 55: 374-9.
111. Romero A.I., Lagging M., Westin J., et al. Interferon (IFN)-gamma-inducible protein-10: association with histological results, viral kinetics, and outcome during treatment with pegylated IFN-alpha 2a and ribavirin for chronic hepatitis C virus infection. J Infect Dis 2006; 194: 895-903.
112. Lagging M., Romero A.I., Westin J., et al. IP-10 predicts viral response and therapeutic outcome in difficult-to-treat patients with HCV genotype 1 infection. Hepatology 2006; 44: 1617-25.
113. Itoh Y., Morita A., Nishioji K., et al. Clinical significance of elevated serum interferon- inducible protein-10 levels in hepatitis C virus carriers with persistently normal serum transaminase levels. J Viral Hepat 2001; 8: 341-8.
114. Mihm U., Herrmann E., Sarrazin U., et al. Association of serum interleukin-8 with virologic response to antiviral therapy in patients with chronic hepatitis C. J Hepatol 2004; 40: 845-52.
115. Neuman M.G., Benhamou J.P., Martinot M., et al. Predictors of sustained response to alpha interferon therapy in chronic hepatitis C. Clin Biochem 1999; 32: 537-45.
116. Panasiuk A., Prokopowicz D., Panasiuk B. Monocyte chemotactic protein-1 and soluble adhesion molecules as possible prognostic markers of the efficacy of antiviral treatment in chronic hepatitis C. World J Gastroenterol 2004; 10: 3639-42.
117. Montes-Cano M.A., Garcia-Lozano J.R., Aguilar-Reina J., et al. CCL2-2518 A/G and CCR2 190 A/G do not influence the outcome of hepatitis C virus infection in the Spanish population. World J Gastroenterol 2007; 13: 2187-92.
118. Frese M., Barth K., Kaul A., et al. Hepatitis C virus RNA replication is resistant to tumour necrosis factor-alpha. J Gen Virol 2003; 84: 1253-9.
119. Abu-Khabar K.S., Armstrong J.A., Ho M. Type I interferons (IFN-alpha and -beta) suppress cytotoxin (tumor necrosis factor-alpha and lymphotoxin) production by mitogen-stimulated human peripheral blood mononuclear cell. J Leukoc Biol 1992; 52: 165-72.
120. Fabris C., Del Forno M., Falleti E., et al. Kinetics of serum soluble tumour necrosis factor receptor (TNF-R) type-I and type-II after a single interferon-alpha (IFN-alpha) injection in chronic hepatitis C. Clin Exp Immunol 1999; 117: 556-60.
121. Neuman M.G., Benhamou J.P., Bourliere M., et al. Serum tumour necrosis factor-alpha and transforming growth factor-beta levels in chronic hepatitis C patients are immunomodulated by therapy. Cytokine 2002; 17: 108-17.
122. Neuman M.G., Benhamou J.P., Ibrahim A., et al. Role of cytokines in the assessment of the severity of chronic hepatitis C and the prediction of response to therapy. Rom J Gastroenterol 2002; 11: 97-103.
123. Larrea E., Garcia N., Qian C., et al. Tumor necrosis factor alpha gene expression and the response to interferon in chronic hepatitis C. Hepatology 1996; 23: 210-7.
124. Zein N.N. Etanercept as an adjuvant to interferon and ribavirin in treatment-naive patients with chronic hepatitis C virus infection: a phase 2 randomized, double-blind, placebo-controlled study. J Hepatol 2005; 42: 315-22.
125. Marinos G., Naoumov N.V., Rossol S., et al. Tumor necrosis factor receptors in patients with chronic hepatitis B virus infection. Gastroenterology 1995; 108: 1453-63.
126. Deutsch M., Hadziyannis S.J. Old and emerging therapies in chronic hepatitis C: an update. J Viral Hepat 2008; 15: 2-11.